Cost-Effectiveness of Empagliflozin for the Treatment of Patients with Type 2 Diabetes Mellitus at Increased Cardiovascular Risk in Greece Επικοινωνία Submitted by Απόστολος Τσάπας on Τρί, 05/29/2018 - 01:48
